This trial is evaluating whether Ribociclib will improve 1 primary outcome in patients with Carcinoma. Measurement will happen over the course of At 8 weeks.
This trial requires 87 total participants across 2 different treatment groups
This trial involves 2 different treatments. Ribociclib is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Around 2 cases of endometrioid carcinoma are diagnosed in the United States every 100 000 people a year. As of 2009, around 4 % of all endometrioid carcinomas were caused by the Epstein-Barr virus.\n" - Anonymous Online Contributor
"Treatment of endometrioid cancer requires surgical removal and lymph node debulking. Chemotherapy options include carboplatinum and taxanes. Radiation therapy, preferably to the pelvis, is the cornerstone of treatment of carcinoma, endometrioid. However, a small number of patients will respond and be durable responders." - Anonymous Online Contributor
"In the past, it was thought that carcinoma, endometrioid, is a form of low-grade or endometrioid endometrial cancer. However, it is not, nor is it always present. Its histopathologic features are more akin to serous carcinomas. The tumour has a good prognosis. But it arises more commonly in postmenopausal women and younger women who are hormonally active. The tumour occurs in an endometrial polyp which is itself a type of hyperplasia. It appears to have undergone neoplastic evolution in the endometrial cells. Thus, the pathogenesis is complex." - Anonymous Online Contributor
"Carcinoma, endometrioid, with vaginal involvement has clear signs. Tumor size and nodal and distant metastatic spread are important factors in predicting the survival of patients." - Anonymous Online Contributor
"Cancer, endometrioid type, shows a pattern similar to endometrioid adenocarcinoma of the ovarian stroma. Both, therefore, may be treated with a radical surgery. On the basis of this report, there may be no benefit to adjuvant radiotherapy." - Anonymous Online Contributor
"The cause of carcinoma, endometrioid is unknown, but may be a result of a combination of factors which present during development. These includes genetics, brain injury, and exposure to certain toxins during pregnancy. These factors may be similar to those involved in the causation of ovarian cancer." - Anonymous Online Contributor
"Ribocylcis does not increase the efficacy of letrozole over placebo in patients with advanced hormone-responsive breast cancer. No difference in the incidence of adverse effects was observed between the two groups." - Anonymous Online Contributor
"Ribociclib was most commonly used in combination with any other agents in clinical trials of BRCA-deficient advanced or metastatic BRCA-mutated cancer. Results from a recent clinical trial can be applied to any BRCA-mutated cancer and might help guide clinical design." - Anonymous Online Contributor
"Ribociclib is typically well tolerated with no evidence of treatment-related harm over three cycles of treatment. Patients should be aware that increased incidence of high blood calcium may be associated with ribociclib treatment." - Anonymous Online Contributor
"Given the excellent survival outcomes after primary therapy and the modest survival after second-line therapy and the high rate of systemic therapy failure in primary and secondary disease, patients with endometrioid should have a high likelihood of survival and might be more likely to tolerate the adverse events associated with systemic therapies and be able to benefit from treatment." - Anonymous Online Contributor
"There are 3 major causes of carcinoma endometrioid that can be attributed to, the causes include a hereditary pattern, inflammation caused by infectious agents, or carcinogenesis." - Anonymous Online Contributor
"The survival rate for carcinoma, endometrioid was 66.4%. If the stage of carcinoma, endometrioid is early stage, it has high survival rate. If the stage is middle or late stage, the survival rate is relatively low." - Anonymous Online Contributor